Invasive Fungal Infection Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: February 09, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 7.21 billion |
|
Revenue Forecast in 2030 |
US$ 10.36 billion |
|
CAGR |
4.10% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Drug Type, Disease Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global invasive fungal infection therapeutics market was valued at US$ 7.21 billion in 2021 and is expected to register a revenue CAGR of 4.10% to US$ 10.36 billion by 2030.
Invasive Fungal Infection Therapeutics Market Fundamentals
Invasive fungal infections (IFIs) are infections where fungi establish themselves in the deep tissues and cause protracted sickness. IFIs are typically found in immunosuppressed and disabled people, caused by yeasts and molds. The main cause of IFI is weak immunity. The disease occurs in bloodstream infections (mycosis) or via secondary transmission to areas such as the eyes, liver, spleen, bone, heart valves, and the central nervous system.
[7564644]
Invasive Fungal Infection Therapeutics Market Dynamics
The rising prevalence of fungal infections and the increasing need for innovative treatments are propelling market revenue growth. This, in turn, is increasing research and development activities. The drugs are highly adopted for the treatment of azoles, polyenes, and echinocandins, and are influencing the market revenue growth. Moreover, increase in the number of pipeline drugs is anticipated to boost the market potential in the coming years.
However, there are several market challenges, such as adverse effects or limited effectiveness of certain antifungal drugs. Moreover, there is a lack of awareness about IFIs and their treatments among healthcare providers and the general population, leading to underdiagnosis and treatment. The limited number of drugs available for the treatment of IFIs, particularly those caused by more resistant species, is a major challenge for this market. The emergence of drug-resistant fungal strains, such as azole-resistant Aspergillus fumigatus, has increased the difficulty of treating IFIs and has limited the effectiveness of existing antifungal drugs.
The high cost of antifungal drugs and the associated healthcare costs, including hospitalization and laboratory tests, presents a major challenge for patients and healthcare systems, particularly in low- and middle-income countries. The complex regulatory process for the approval of new antifungal drugs, including the requirement for extensive clinical trials and safety testing, presents a significant challenge for developing and commercializing new antifungal drugs.
Invasive Fungal Infection Therapeutics Market Ecosystem
The global invasive fungal infection therapeutics market has been analyzed from three perspectives: drug type, disease type, and region.
Invasive Fungal Infection Therapeutics Market by Drug Type
[86745654]
In terms of drug type, the global invasive fungal infection therapeutics market is segmented into polyenes, echinocandins, triazoles, flucytosine, and others.
The triazoles segment dominated the global market in 2021. Patients undergoing chemotherapy and HSCT (hematopoietic stem cell transplantation) are recommended to use triazole antifungal drugs. Furthermore, triazoles offer a wide range of activities and higher safety standards. In addition, triazoles provide easy and enhanced absorption and distribution properties. Polyenes are a class of antifungal drugs that have been used for the treatment of IFIs. They work by binding to ergosterol, an important component of fungal cell membranes, leading to a disturbance in membrane function and cell death.
In recent years, the trend in the treatment of IFIs has shifted towards the use of more targeted and less toxic antifungal agents, such as echinocandins and azoles. However, polyenes still play an important role in the treatment of certain types of fungal infections, especially those caused by more resistant species. Additionally, there has been increasing interest in the combination of different antifungal drugs, including polyenes, to improve treatment outcomes and prevent the development of resistance.
Invasive Fungal Infection Therapeutics Market by Disease Type
According to disease type, the global invasive fungal infection therapeutics market is segmented into invasive aspergillosis, coccidioidomycosis and scedosporiosis, candidaemia and invasive candidiasis cryptococcal meningitis, intra-abdominal candidiasis, mucormycosis, invasive rhinosinusitis, and others (esophageal candidiasis, acute pulmonary histoplasmosis).
The invasive candidiasis segment accounts for the majority of the market revenue share. Invasive candidiasis is caused by Candida (a type of fungus). This is a dangerous infection affecting the blood, heart, brain, eyes, bones, and other body parts. People with weak immunity are more prone to acquire the disease. Furthermore, increased organ transplant cases often lead to infection, as immunosuppressors are extensively used here.
The market for antifungal drugs to treat invasive aspergillosis, a life-threatening fungal infection caused by Aspergillus species, has been growing in recent years. This revenue growth is driven by several factors, including the increasing prevalence of immunocompromised patients, such as those with cancer or undergoing organ transplantation, and the increasing incidence of nosocomial (hospital-acquired) fungal infections. Additionally, the development of new antifungal drugs and the growing awareness of the importance of early diagnosis and prompt treatment of invasive aspergillosis are also contributing to the revenue growth of this segment of the market.
Invasive Fungal Infection Therapeutics Market by Region
Geographically, the global invasive fungal infection therapeutics market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America dominates the global market due to increased incidence of IFIs and growing public awareness of invasive fungal illnesses. The market in Europe is characterized by rising public awareness and increased focus of pharmaceutical and biotechnological companies in introducing new and innovative products. The Asia Pacific invasive fungal infection therapeutics market is influenced by factors such as the increasing prevalence of diseases, rising health awareness, and high investments in R&D activities. Japan has dominated the market in the Asia Pacific region.
In the Middle East and Africa region, the invasive fungal infection therapeutics market is growing, driven by several factors, including the increasing prevalence of immunocompromised patients, such as those with HIV/AIDS, and the increasing incidence of nosocomial (hospital-acquired) fungal infections. Additionally, the increasing awareness of the importance of early diagnosis and prompt treatment of IFIs, as well as the improving healthcare infrastructure and increasing healthcare expenditure in many countries in the region, are also contributing to the revenue growth of the Middle East & Africa invasive fungal infection therapeutics market. However, the market for antifungal therapeutics in the Middle East and Africa is still in its nascent stage. It faces several challenges, including limited healthcare access and affordability, as well as a lack of awareness about IFIs and their treatments among healthcare providers and the general population. Despite these challenges, the invasive fungal infection therapeutics market in the Middle East and Africa region is expected to grow in the coming years, driven by increasing demand for new and more effective treatments and ongoing efforts to improve healthcare access and affordability.
Invasive Fungal Infection Therapeutics Market Competitive Landscape
The prominent players operating in the global invasive fungal infection therapeutics market are:
The rising prevalence of fungal infections and the increasing need for innovative treatments propel market revenue growth. This, in turn, is increasing research and development activities. Azoles, polyenes, and echinocandins are highly prescribed for treating IFIs, influencing the market revenue growth. Moreover, many pipeline drugs are anticipated to boost the market potential in the coming years.
Abbott Laboratories Inc., Cidara Therapeutics Inc., Basilea Pharmaceutical, Pfizer Inc., and Astellas Pharma Inc. are among the top players in the global market.
The global invasive fungal infections market is likely to register limited revenue growth due to adverse effects associated with antifungals.
Invasive fungal infection (IFI) is a condition where fungi establish themselves in the deep tissues and organs and cause protracted sickness.
The global invasive fungal infection therapeutics market is expected to register a revenue CAGR of 4.10% during the forecast period from 2022 to 2030.
*Insights on financial performance is subject to availability of information in public domain